

EULAR COVID-19 Database

for rheumatologists and other clinicians


The EULAR - COVID-19 Database is a European paediatric and adult database (in collaboration with the Paediatric Rheumatology European Society (PReS)) to monitor and report on outcomes of "Coronavirus Disease 2019" (COVID-19) occurring in patients with rheumatic and musculoskeletal diseases (RMDs).

Weekly reporting - data extract: 13th July 2020

Total number of patients to 13th July 2020: 2488

To date there have been 2488 patients reported to the EULAR COVID-19 registry from 31 of countries. There have been 1204 hospitalisations and 273 deaths due to COVID-19.

Figure 1: Cumulative number of cases (by COVID-19 diagnosis date) from 7th March 2020 until 13th July 2020 (current data extract).



EULAR COVID-19 Database

for rheumatologists and other clinicians

Table 1: Patient Demographics

		All patients
Total number		2488
Gender	Female	1595 (64%)
N (%)	Male	890 (36%)
	Other / Unknown	3 (<1%)
Age	Median (IQR)	58 (47 - 70)
	Range (min to max)	4 to 98
Age categories (years)	<18	32 (1%)
N (%)	18-40	338 (14%)
<i>Note: 3 patients are missing age data</i>	41-60	1005 (40%)
	61-more	1110 (45%)
Country	Austria	2 (<1%)
N (%)	Belgium	4 (<1%)
	Bosnia and Herzegovina	2 (<1%)
	Croatia	7 (<1%)
	Czech Republic	5 (<1%)
	Cyprus	3 (<1%)
	Finland	1 (<1%)
	France	810 (33%)
	Germany	236 (9%)
	Greece	2 (<1%)
	Hungary	1 (<1%)
	Israel	3 (<1%)
	Italy	318 (13%)
	Latvia	2 (<1%)
	Moldova	1 (<1%)
	Netherlands	30 (1%)
	Norway	3 (<1%)
	Poland	3 (<1%)
	Portugal	53 (2%)
	Republic of Ireland	86 (3%)
	Romania	7 (<1%)
	Russia	11 (<1%)
	Serbia	1 (<1%)
	Slovak Republic	1 (<1%)
	Slovenia	3 (<1%)
	Spain	259 (10%)
	Sweden	96 (4%)
	Switzerland	4 (<1%)

EULAR COVID-19 Database

for rheumatologists and other clinicians

Turkey	62 (2%)
Ukraine	1 (<1%)
United Kingdom	471 (19%)

Table 2: Disease information

		All Patients
Rheumatology Diagnosis	Rheumatoid Arthritis (RA)	912 (37%)
N (%)	Spondyloarthritis (including Axial spondyloarthritis, ankylosing spondylitis, other spondyloarthritis, reactive arthritis)	361 (15%)
	Psoriatic arthritis	329 (13%)
	Systemic Lupus Erythematosus	158 (6%)
	Systemic sclerosis	90 (4%)
	Polymyalgia rheumatic	84 (3%)
	Sjogrens syndrome	73 (3%)
	Gout	64 (3%)
	Giant cell arteritis	56 (2%)
	Other inflammatory arthritis	56 (2%)
	ANCA-associated vasculitis (e.g., GPA, EGPA)	49 (2%)
	Inflammatory myopathy (e.g. dermatomyositis, polymyositis)	46 (2%)
	Other vasculitis including Kawasaki disease	37 (1%)
	Autoinflammatory syndrome (including TRAPS, CAPS, FMF)	30 (1%)
	Behcets	25 (1%)
	Undifferentiated connective tissue disease	25 (1%)
	Juvenile idiopathic arthritis (polyarthritis)	24 (1%)
	Sarcoidosis	23 (1%)
	Anti-phospholipid antibody syndrome	23 (1%)
	Mixed connective tissue disease	15 (1%)
	Ocular inflammation	13 (1%)
	Juvenile idiopathic arthritis (oligoarthritis)	12 (<1%)
	Systemic juvenile idiopathic arthritis	7 (<1%)
	IgG4-related disease	6 (<1%)
	Chronic recurrent multifocal osteomyelitis	None
	Inclusion body myositis (IBM)	None
	Localised scleroderma (morphea)	None
<hr/>		
Comorbidities	None stated	701 (28%)
N (%)	Lung disease (includes ILD, COPD, asthma, other lung disease)	440 (18%)
<i>Note: 104 patients are missing comorbidity data</i>	Diabetes	284 (11%)
	Hypertension	738 (30%)
	Cardiovascular disease	304 (12%)

EULAR COVID-19 Database

for rheumatologists and other clinicians

Required Hospitalisation N (%)	Yes	1204 (48%)
	No	705 (28%)
	Missing	579 (23%)

Top 5 symptoms reported N (%)	Fever	1763 (71%)
	Cough	1624 (65%)
	Shortness of breath	1143 (46%)
	Diarrhoea, vomiting	617 (25%)
	Fatigue	532 (21%)

DMARDs at time of COVID N (%)	Any DMARD	1973 (79%)
	<i>csDMARDs</i>	1394 (56%)
	<i>bDMARDs</i>	952 (38%)
	<i>tsDMARDs</i>	70 (3%)
